Alescat, autologous lymphocyte-based therapy for the treatment of solid cancers
Alecsat cells are CD8-positive cytotoxic T lymphocytes and natural killer cells. These cells can specifically recognize and kill cancer cells. Following isolation of the CD8-positive cytotoxic T lymphocytes and natural killer cells from patient blood, they are returned to the patient to boost an immune response against the cancer cells.
Preliminary clinical phase I/II data from 13 late-stage prostate cancer patients show that Alescat treatment is well tolerated and has no side effects. In most of the patients, the treatment also showed indications of clinical effect.
Read More
Regenerative cells were not specified by the originator.
Read More
Product Information for
Alescat, autologous lymphocyte-based therapy for the treatment of solid cancers